CoChat

Diabetes, metformin use, and colorectal cancer survival in postmenopausal women

Open access
Cossor, Furha Iram, Adams-Campbell, Lucile L., Chlebowski, Rowan T., Gunter, Marc J., Johnson, Karen, Martell, Robert E., McTiernan, Anne, Simon, Michael S., Rohan, Thomas, Wallace, Robert B., Paulus, Jessica K. · 2013 · Cancer Epidemiology
Cited by 60

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background Observational studies have associated metformin use with lower colorectal cancer (CRC) incidence but few studies have examined metformin’s influence on CRC survival. We examined the relationships among metformin use, diabetes, and survival in postmenopausal women with CRC in the Women’s Health Initiative (WHI) Clinical Trials and Observational Study. Methods 2,066 postmenopausal women with CRC were followed for a median of 4.1 years, with 589 deaths after CRC diagnosis from all causes and 414 deaths directly attributed to CRC. CRC-specific survival was compared among women with diabetes with metformin use (n=84); women with diabetes with no metformin use (n=128); and women without diabetes (n=1854). Cox proportional hazard models were used to estimate associations among metformin use, diabetes and survival after CRC. Strategies to adjust for potential confounders included: multivariate adjustment with known predictors of colorectal cancer survival and construction of a propensity score for the likelihood of receiving metformin, with model stratification by propensity score quintile. Results After adjusting for age and stage, CRC specific survival in women with diabetes with metformin use was not significantly different compared to that in women with diabetes with no metformin use (HR 0.75; 95% CI 0.40 –1.38, p=0.67) and to women without diabetes (HR 1.00; 95% CI 0.61 – 1.66, p=0.99). Following propensity score adjustment, the HR for CRC-specific survival in women with diabetes with metformin use compared to non-users was 0.78 (95% CI 0.38 – 1.55, p=0.47) and for overall survival was 0.86 (95% CI 0.49 – 1.52; p=0.60). Conclusions In postmenopausal women with CRC and DM, no statistically significant difference was seen in CRC specific survival in those who used metformin compared to non-users. Analyses in larger populations of colorectal cancer patients are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.canep.2013.04.015

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 60

Metadata

Authors
Cossor, F. I., Adams-Campbell, L. L., Chlebowski, R. T., Gunter, M. J., Johnson, K., Martell, R. E., McTiernan, A., Simon, M. S., Rohan, T., Wallace, R. B., & Paulus, J. K.
Venue
Cancer Epidemiology
Publisher
Elsevier BV
Published
2013-10
Volume
37
Issue
5
Pages
742-749
ISSN
1877-7821 (ISSN-L)
OpenAlex
W2160108442
Cited by
60
References
4
FWCI
2.42
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. https://app.cochat.ai/papers/10.1016/j.canep.2013.04.015
The paper
Cossor, F. I., Adams-Campbell, L. L., Chlebowski, R. T., Gunter, M. J., Johnson, K., Martell, R. E., McTiernan, A., Simon, M. S., Rohan, T., Wallace, R. B., & Paulus, J. K. (2013). Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiology. https://doi.org/10.1016/j.canep.2013.04.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.